Depo-Provera

DRUG4 trials

Sponsors

Thomas Cherpes, DVM, MD, University of Utah, University of Minnesota, Tanta University

Conditions

Birth ControlContraceptionContraceptive ImplantContraceptive MethodsEmergency ContraceptionHIV/AIDSIUDInitiation of Depo-Provera (DMPA)

Unknown Phase

Modulation of Mucosal and Systemic Immunity by Hormonal Contraceptives

TerminatedNCT01750476

Thomas Cherpes, DVM, MDInitiation of Depo-Provera (DMPA), Initiation of Mirena (LNG-IUD), Initiation of Oral Contraception (OC)

Start: 2012-12-31End: 2013-06-30Updated: 2014-01-07

Quick Start of Highly Effective Contraception

Active, not recruitingNCT02076217

University of UtahBirth Control, Contraception, Contraceptive Implant +2

Start: 2014-02-28End: 2026-01-31Target: 1030Updated: 2024-12-13

Modifiers of Tenofovir in the Female Genital Tract

CompletedNCT03377608

University of MinnesotaContraception, HIV/AIDS

Start: 2017-11-17End: 2018-04-02Updated: 2018-05-01

Progesterone Containing Contraceptive Methods on Endogenous Progesterone Level

CompletedNCT05742503

Tanta UniversityContraceptive Methods, Progesterone

Start: 2021-03-30End: 2022-03-30Updated: 2023-02-24

Related Papers

Depot Medroxyprogesterone Acetate and the Vaginal Microbiome as Modifiers of Tenofovir Diphosphate and Lamivudine Triphosphate Concentrations in the Female Genital Tract of Ugandan Women: Implications for Tenofovir Disoproxil Fumarate/Lamivudine in Preexposure Prophylaxis

Clinical Infectious Diseases2019-05-2416 citations